Samuel Moed

Venture Partner at aMoon

Mr. Samuel Moed is a recently retired executive from Bristol Myers Squibb (BMS; NYSE: BMY), a global biopharma company focused on innovative therapeutics. In his most recent capacity as Senior Vice President, Corporate Strategy, Mr. Moed led the strategic direction of the company with close linkage to all of its major businesses, functions, and geographies. Recent focus was on the $90 billion acquisition and integration of Celgene by BMS. Previously, Mr. Moed oversaw strategy for BMS’s Worldwide Pharmaceuticals Group, encompassing a range of global strategic initiatives, and managed a global portfolio of strategic alliances. He also led a number of businesses including as President of U.S. Pharmaceuticals and as President of Worldwide Consumer Healthcare.

Location

New York, United States

Links


Org chart

No direct reports

Teams


Offices

This person is not in any offices


aMoon

aMoon is a global HealthTech and Life Sciences investment fund based in Israel. As Israel’s largest HealthTech fund, with over $1.1 billion AUM, They partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare.


Industries

Employees

51-200

Links